Alan Schaeffer, MD
Ophthalmology · Southaven, MSNPI 1912937574
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,728 of the $6,700 with a category attached, or 85.5%. It is spread thinly across 23 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations.
Across 130 payments — averaging $51.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alcon$1K
- Mallinckrodt Hospital Products Inc.$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$813
- Amgen$360
- Glaukos Corporation$347
- plus $2K from 17 others
What the payments were for
- Travel & lodging$74811%
- Food & beverage$5,72885%
- Education$931%
- Gifts$451%
- Entertainment$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 34 | $1,325 |
| Alcon | 9 | $1,204 |
| Mallinckrodt Hospital Products Inc. | 31 | $1,138 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $813 |
| Amgen(2 entities) | 3 | $360 |
| Glaukos Corporation | 3 | $347 |
| Bausch & Lomb Americas Inc. | 5 | $302 |
| Ocular Therapeutix, Inc. | 5 | $204 |
| Coopervision Inc. | 2 | $193 |
| Genentech USA, Inc. | 1 | $132 |
| Harrow Eye, LLC | 1 | $117 |
| Sight Sciences, Inc. | 4 | $107 |
| Optos, Inc. | 1 | $85 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $85 |
| Thea Pharma Inc. | 3 | $67 |
| Sun Pharmaceutical Industries Inc. | 2 | $41 |
| Biotissue Holdings Inc. | 2 | $38 |
| Kala Pharmaceuticals, Inc. | 2 | $34 |
| Ivantis, Inc | 2 | $28 |
| Carl Zeiss Meditec USA, Inc. | 1 | $23 |
| Iridex Corporation | 1 | $23 |
| Dompe US, Inc. | 1 | $22 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,700 in reported general payments places this provider in the 85th percentile of 150 ophthalmology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 260 | $140,403 |
| RestasisCyclosporine | 42 | $34,835 |
| CombiganBrimonidine Tartrate/Timolol | 64 | $33,029 |
| Prednisolone Acetate | 417 | $30,431 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 48 | $11,682 |
| Latanoprost | 816 | $9,552 |
| VyzultaLatanoprostene Bunod | 15 | $8,524 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 372 | $7,465 |
| Travoprost | 32 | $5,924 |
| Ciprofloxacin Hcl | 308 | $5,648 |
| Brimonidine Tartrate | 140 | $3,283 |
| Acetazolamide ErAcetazolamide | 41 | $2,297 |
| Bacitracin | 13 | $1,515 |
| Dorzolamide Hcl | 61 | $1,015 |
| Timolol Maleate | 79 | $1,012 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $1,325 | $208,267366 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $302 | $8,52415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 150 ophthalmology providers in Mississippi.
Other ophthalmology in Southaven
- Michael WertheimerSouthaven$6K
- Kiper NelsonHattiesburg$234K
- John ParkerTupelo$72K
- Joseph ChildsTupelo$42K
- Heather HancockJackson$39K
- Leslie AdenFlowood$38K
- Adam QuinnHattiesburg$29K
- Mark KoskoJackson$27K
- James ShippOxford$21K
- Calvin BrownOlive Branch$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.